Connect with us

Finance

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Published

on

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
  • Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)

  • Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolled

  • Appointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical Officer

  • Interim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025

  • Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2024, and provided a general business update.

“I am pleased with the continued progress we made across our clinical programs. The pace of enrollment for the PHOENIX trial remains strong, and in the quarter, we completed the Phase 1b DRAGON II trial of Tinlarebant in Stargardt disease in Japan and dosed the first patient in the Phase 2/3 portion of the trial. We are well-positioned to achieve critical milestones and look forward to providing an update on the interim analysis from our pivotal Phase 3 DRAGON trial toward the end of 2024 or early 2025,” said Dr. Tom Lin, Chairman and CEO of Belite. “In the quarter, we were also excited to welcome Dr. Scholl, a leading global expert in Stargardt disease and age-related macular degeneration, as our Chief Medical Officer. Dr. Scholl’s decision to join Belite following his experience as Chair of the Data and Safety Monitoring Board for both our Phase 2 and Phase 3 Stargardt disease trials further validates our belief in Tinlarebant’s immense potential.”

Third Quarter 2024 Business Highlights and Upcoming Milestones:

Clinical Highlights

Tinlarebant (LBS-008) is an oral, potent, once daily retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical to normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA (the advanced form of dry age-related macular degeneration (dry AMD) leading to retinal cell death and loss of vision.

Advertisement

Advertisement

Finance

Donating Stock Instead of Cash Is the 2-for-1 Deal You’ll Love at Tax Time

Published

on

Donating Stock Instead of Cash Is the 2-for-1 Deal You’ll Love at Tax Time

For many families, the holiday season comes with familiar rituals: untangling last year’s Christmas lights, decorating the tree and rediscovering ornaments we swore we’d organize “better next year.”

Charitable giving should feel just as joyful and natural — but for many households, it’s also a moment when good intentions collide with inefficient habits.

Continue Reading

Finance

Aerodrome Finance Hit by ‘Front-End’ Attack, Users Urged to Avoid Main Domain

Published

on

Aerodrome Finance Hit by ‘Front-End’ Attack, Users Urged to Avoid Main Domain

Aerodrome Finance, a leading decentralized exchange on Coinbase’s Base network with $400 million in total value locked, was targeted in a front-end attack late Friday, prompting urgent warnings for users to avoid its primary domains.

The incident appears to be a DNS hijacking of Aerodrome’s centralized domains, which allowed attackers to reroute users to lookalike phishing sites designed to trick them into signing malicious wallet transactions to separate them from their funds. Users are advised to instead rely on Aerodrome’s decentralized domains. Aerodrome has asked My.box, the domain provider, to contact them over a potential exploit of their systems.

These attacks do not compromise the underlying smart contracts, which manage user funds and protocol logic on-chain. At the time of writing, it’s unconfirmed whether the attack has led to any losses or how many users have been affected. Liquidity pools and protocol treasuries remain intact, according to Aerodrome.

Aerodrome’s team has been posting real-time updates on X, urging users not to access the compromised domains, aerodrome.finance and aerodrome.box, and instead use decentralized ENS mirrors like aero.drome.eth.limo. To reduce risk, the team recommends revoking recent token approvals using tools like Revoke.cash and avoiding signing any transactions from unverified domains.

New attack

Aerodrome has experienced similar front-end attacks before, including two in late 2023 that resulted in approximately $300,000 in user losses.

Advertisement

This latest attack comes just days after Aerodrome announced a merger with Velodrome, consolidating liquidity across Base and Optimism under the new “Aero” ecosystem. Despite the disruption, the AERO token price remained stable at around $0.67, up 2% over the last 24 hours.

The investigation is ongoing.

Continue Reading

Finance

Incredible year-long spending experiment exposes mistakes you’re probably making

Published

on

Incredible year-long spending experiment exposes mistakes you’re probably making
The forthcoming book follows her journey of one year without buying anything new and how it changed her relationship with money and her self-worth. (Source: Emma Edwards/Instagram)

Financial behaviour specialist Emma Edwards, founder of The Broke Generation, is sharing her radical personal finance experiment: a whole year without buying a single item of clothing.

No new outfits, no second-hand finds, not even rentals. What began as a no-buy challenge soon became a powerful lesson in self-worth, resilience, and the surprising freedom of living with less.

In the exclusive extract below, Emma shares the six buying patterns we get trapped into thinking we actually need.

RELATED

The impact of our consumption habits creates an environment where we’re cornered from every angle. We have a collection of clothes that don’t work together, don’t make us feel good and don’t allow us to express ourselves the way we want to, which leaves us looking externally for what we’re not getting. The problem is, when we look externally, we buy more and more of the same.

Advertisement

Unravelling that idea of what can happen when we’re in a ‘yes’ state, a state of openness to consumption even though our intentions might suggest otherwise, got me curious about some of the unhelpful buying cycles I’d been stuck in. I really leaned into understanding how I ended up with the wardrobe I currently had, and what I could learn from the mistakes I made over and over again.

I realised that if I could establish the mistakes I was making and the ways I was buying the wrong things, I’d stop feeling compelled to buy more and more over time. Here are some of the patterns I uncovered in my wardrobe, and that I’ve seen in others’ too.

Once I liked something in one colour (often black), I’d giddily run out and buy it in another colour, thinking I was making some kind of ultra-smart decision and capitalising on what I loved. I’m going to give you a piece of advice now that I hope you’ll remember for many years. If you ever utter the words ‘I’m going to go and get this in another colour’ – run. It’s a trap. You probably won’t like the other colour, and it’ll just sit in your wardrobe and collect dust.

There are certain things in my wardrobe that I struggled to wear confidently outside of one specific outfit silo. Usually, this is a sure-fire sign that I’d bought it in a very specific context, like copying or replicating an outfit I’d seen someone else wear.

Advertisement

Continue Reading

Trending